Analysis of data from a cohort of patients with prostate cancer from the Memorial Sloan Kettering Cancer Center (MSKCC) [31] showed that high levels of RhoH in the tumour samples correlate with decreased recurrence-free survival (RFS) (determined by measuring prostate-specific antigen (PSA) levels) (Fig. 4c). Here, PROS1 is linked to neoplasm.